Officially published! A new TRPV1 agonist MSP20, which binds to the vanilloid site and desensitizes TRPV1. Our structural and preclinical studies highlight the potential of MSP20 as a long-lasting analgesic with neuroprotective effects. https://t.co/YT0xVt61A9
https://t.co/mUuSd92TLe
New preprint from our lab!
Solving antagonist-bound GPCR structures is becoming easier with fusion markers, but linker optimization between GPCR and marker is still a bottleneck. (1/2)